Introduction: inhaled insulins:potential therapies for diabetes mellitus

References

• IDF Diabetes Atlas. Available from http://www.eatlas.idf.org/Prevalence/All_diabetes/ [Last accessed 18 Oct 2005]
   Google Scholar
• The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: 837–53
   Google Scholar
• Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes (clinical practice recommendations). Diabetes Care 2006;29(Suppl 1):S4–42
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management – 2002 update. Endocr Pract 2002;8(Suppl 1):40–82
   PubMedGoogle Scholar
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus of the European Diabetes Policy Group 1999. Diabet Med 1999;16:716–30
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care 2004;27:17–20
   PubMed Web of Science ®Google Scholar
• Liebl A, Mata M, Eschwege E, for the ODE-2 Advisory Board. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45:S23–8
   Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26: S18–24
   PubMed Web of Science ®Google Scholar
• Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292–8
   Google Scholar
• Heineman L, Heise T. Current states of the development of inhaled insulin. Br J Diabetes Vasc Dis 2004;4:295–301
   Google Scholar
• Patton J. Pulmonary delivery of insulin. Curr Med Res Opin 2006;22(Suppl 3):S5–S11
   Google Scholar
• Patton J, Bukar J, Eldon M. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781–801
   PubMed Web of Science ®Google Scholar
• Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077–82
   PubMed Web of Science ®Google Scholar
• Quattrin T, Belanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004;27:2622–7
   PubMed Web of Science ®Google Scholar
• Skyler J, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in subjects with type 1 diabetes: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630–5
   PubMed Web of Science ®Google Scholar
• Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004;27:2356–62
   PubMed Web of Science ®Google Scholar
• Norwood P, Dumas R, England RD, et al. Inhaled insulin (ExuberaÒ) achieves tight glycemic control and is well tolerated in patients with type 1 diabetes. Diabetologia 2005;48\(Suppl 1):A30 [abstract 73]
   Google Scholar
• Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin (ExuberaÒ) improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med 2005;143: 549–58
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 2005;28:1922–8
   PubMed Web of Science ®Google Scholar
• Dreyer M, for the Exubera Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type diabetes patients poorly controlled with oral monotherapy. Diabetologia 2004;47\(Suppl 1):A44
   Google Scholar
• Brain JD. Unlocking the opportunity of tight glycemic control. Inhaled insulin: safety. Diabetes Obes Metab 2005;7(Suppl 1): S14–8
   Google Scholar
• Del Prato S. Inhaled insulins: the present and future of diabetes therapy. Curr Med Res Opin 2006;22(Suppl 3): S13–S19
   Google Scholar
• Fabbri L. Pulmonary safety of inhaled insulins: a review of the current data. Curr Med Res Opin 2006;22(Suppl 3):S21–S28
   Google Scholar
• Rosenstock J, Baughman RA, Rivera-Schaub T, et al. A randomized, double-blind, placebo-control study of the efficacy and safety of inhaled Technosphere insulin in patients with type 2 diabetes (T2DM). Diabetes 2005;54\(Suppl 1):A357
   Google Scholar
• Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27: 162–7
   PubMed Web of Science ®Google Scholar
• Hausman M, Dellweg S, Heinemann L, et al. Add-on therapy with Kos inhaled insulin is as efficacious as add-on therapy with Lantus in poorly controlled type 2 diabetic patients treated with sulfonylureas or metformin. Diabetologia 2005;48\(Suppl 1): A297 [abstract 817]
   Google Scholar
• Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49:891–9
   PubMed Web of Science ®Google Scholar
• Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28: 427–8
   PubMed Web of Science ®Google Scholar